Comprehensive Perspective Of Current And Upcoming Breast Cancer Blood Biomarkers

Breast cancer is one of the most common malignancies and the second leading cause of cancer deathamong women which can be prevented by early diagnosis so as to treat in pro-invasive state. In therecent years, a wide range of breast cancer bio markers has been investigated in several studies,such as genetic, epigenetic, proteomic and imaging bio markers that can be used for diagnosis,staging and prognosis of this disease. Each biomarker has its own benefit and draw-back. Althoughtechnological advances in the field of medicine has enabled us to evaluate many of thesebiomarkers, but still noninvasive methods has its own advantages. As breast cancer leaves somemarkers in the blood, analyzing the blood sample as a source of tumor markers can be counted as anoninvasive and low-cost assay for general screening which can provide valuable information forthe clinical oncologist. Also, it can help in early detection resulting in saving more options fortreatment. Therefore, categorizing blood breast cancer bio markers by their characteristics such asstructure, function, measuring assay, specificity and efficiency could assist in choosing theappropriate bio marker for obtaining clinically relevant data about the presence or absence of thedisease and its evolution as well as improving therapy. In this regard, the current review provides abrief report on blood tumor markers of breast cancer already exist in clinical practice and alsoupcoming bio markers, such as CA 15.U, CA 27.29, Carcinoembryonic antigen (CEA), RS/DJ-1, Tissuetypeplasminogen activator (TPS), Human epidermal growth factor receptor 2 (HER-2/neu), freecirculating DNA, etc. An inclusive understanding of the blood tumor markers of breast cancer, as aregularly requested test by the oncologist, which is noninvasive and economic efficient assay, mayprovide opportunities for enhancing the breast cancer management by helping in early detectionand cancer prevention.